Lazard Capital raised its price target for Integra LifeSciences shares to $48 from $44 after leaving meetings with management increasingly optimistic about the company. The firm expects Integra to beat consensus expectations in the back half of 2012 and thinks the company's October 24 analyst day could prove a small catalyst for shares. Lazard Capital keeps a Buy rating on Integra, which closed yesterday at $41.30 per share.
- Investment & Company Information
- Integra LifeSciences